Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Non-Current Deffered Revenue (2017 - 2025)

Historic Non-Current Deffered Revenue for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $3.0 million.

  • Innate Pharma's Non-Current Deffered Revenue fell 3288.64% to $3.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $3.0 million, marking a year-over-year decrease of 3288.64%. This contributed to the annual value of $3.0 million for FY2024, which is 3924.39% down from last year.
  • Innate Pharma's Non-Current Deffered Revenue amounted to $3.0 million in Q2 2025, which was down 3288.64% from $3.0 million recorded in Q4 2024.
  • Over the past 5 years, Innate Pharma's Non-Current Deffered Revenue peaked at $33.2 million during Q2 2021, and registered a low of $3.0 million during Q2 2025.
  • For the 5-year period, Innate Pharma's Non-Current Deffered Revenue averaged around $11.2 million, with its median value being $6.5 million (2023).
  • The largest annual percentage gain for Innate Pharma's Non-Current Deffered Revenue in the last 5 years was 2537.46% (2021), contrasted with its biggest fall of 9983.78% (2021).
  • Quarter analysis of 5 years shows Innate Pharma's Non-Current Deffered Revenue stood at $29.1 million in 2021, then plummeted by 72.2% to $8.1 million in 2022, then crashed by 38.52% to $5.0 million in 2023, then tumbled by 39.24% to $3.0 million in 2024, then fell by 1.46% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q2 2025, $3.0 million for Q4 2024, and $4.4 million during Q2 2024.